RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of ...

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to USD $16.25 million from Takeda and mid-single digit royalties on ...

At last, the stage was set for lifesaving blood transfusions. No more lambs’ or calves’ blood; no more transfusions from whoever happens to be in the room at the time – science now knew that humans ...

Cell and gene therapies harbor great hopes for biomedicine. They are becoming increasingly important for diseases that are ...

B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric ...

TCG Labs Soleil’s Juri Biosciences is offering EpimAb Biotherapeutics up to $210 million biobucks for exclusive licensing ...